The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Carel le Roux graduated from medical school in Pretoria, South Africa. He completed his specialist training in metabolic medicine at St Bartholomew’s Hospital, London, UK and Hammersmith Hospital, London, UK, and his PhD at Imperial College London, London, UK, where he was later promoted to Reader. Professor le Roux currently coordinates the Innovative Medicines Initiative project SOPHIA, and previously received a President of Ireland Young Researcher award, Clinician Scientist award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research fellowship for his work on how the gut talks to the brain.